Neutralizing Autoantibodies Against IL-10 in Inflammatory Bowel Disease

Summary We discovered high titer neutralizing autoantibodies against interleukin-10 (anti-IL-10) in a child with infantile onset IBD, phenocopying inborn errors of IL-10 signalling. Following B cell depletion and associated decline in the anti-IL-10 titer, conventional IBD therapy could be withdrawn. A second child with neutralizing antibodies against IL-10 displayed a milder course of IBD and has been managed without B cell depletion. We conclude that neutralizing autoantibodies against IL-10 may be a causative or modifying factor in IBD, with potential implications for therapy.

• Publication year

  2024

• Venue

  New England Journal of Medicine

• Publication date

  2024-04-19

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1056/NEJMoa2312302PMID 39083772PMCID 7616361
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Anti-integrin αvβ6 autoantibodies are a novel biomarker that antedate ulcerative colitis.

  2023cited by this paper
• Anti-cytokine autoantibodies: mechanistic insights and disease associations

  2023cited by this paper
• Genetics of circulating inflammatory proteins identifies drivers of immune-mediated disease risk and therapeutic targets

  2023cited by this paper
• Human Inborn Errors of Immunity: 2022 Update on the Classification from the International Union of Immunological Societies Expert Committee

  2022influential reference
• Large-scale sequencing identifies multiple genes and rare variants associated with Crohn’s disease susceptibility

  2022cited by this paper
• Neutralizing Anti-Granulocyte Macrophage-Colony Stimulating Factor Autoantibodies Recognize Post-Translational Glycosylations on Granulocyte Macrophage-Colony Stimulating Factor Years Before Diagnosis and Predict Complicated Crohn’s Disease

  2022cited by this paper
• Deconvolution of monocyte responses in inflammatory bowel disease reveals an IL-1 cytokine network that regulates IL-23 in genetic and acquired IL-10 resistance

  2020cited by this paper
• Autoantibodies against cytokines: phenocopies of primary immunodeficiencies?

  2020cited by this paper
• Anti-IL-10 antibody in systemic lupus erythematosus

  2019cited by this paper
• IL-10 encoded by viruses: a remarkable example of independent acquisition of a cellular gene by viruses and its subsequent evolution in the viral genome.

  2014cited by this paper
• Evidence for non-neutralizing autoantibodies against IL-10 signalling components in patients with inflammatory bowel disease

  2014cited by this paper
• Loss of interleukin-10 signaling and infantile inflammatory bowel disease: implications for diagnosis and therapy.

  2012cited by this paper
• Pediatric modification of the Montreal classification for inflammatory bowel disease: The Paris classification

  2011cited by this paper
• Infant colitis--it's in the genes.

  2010cited by this paper
• Inflammatory bowel disease and mutations affecting the interleukin-10 receptor.

  2009cited by this paper
• Patients with inflammatory bowel disease may have a transforming growth factor‐β‐, interleukin (IL)‐2‐ or IL‐10‐deficient state induced by intrinsic neutralizing antibodies

  2009cited by this paper
• Pulmonary alveolar proteinosis caused by deletion of the GM-CSFRα gene in the X chromosome pseudoautosomal region 1

  2008cited by this paper
• IL-23 plays a key role in Helicobacter hepaticus–induced T cell–dependent colitis

  2006cited by this paper
• Idiopathic Pulmonary Alveolar Proteinosis as an Autoimmune Disease with Neutralizing Antibody against Granulocyte/Macrophage Colony-Stimulating Factor

  1999cited by this paper
• Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes

  1991cited by this paper

• Sensing strategies for disease biomarkers in saliva: current status and future trends

  2026cites this paper
• Expanding the scope of human immunology in the Journal of Human Immunity

  2026cites this paper
• Toward Integration of Molecular Measures and Artificial Intelligence-Based Assessments With Clinical End Points in Inflammatory Bowel Disease.

  2026cites this paper
• Disease‐causing STAT3 variants can be discriminated by a functional flow cytometry test

  2026cites this paper
• Therapeutic Effect of Arginine, Glutamine and β-Hydroxy β-Methyl Butyrate Mixture as Nutritional Support on DSS-Induced Ulcerative Colitis in Rats

  2026cites this paper
• B Cell Dysregulation in IBD: From Pathophysiology to Therapeutic Targeting.

  2026cites this paper
• Chiral Zinc Sulfide Nanoparticles Scavenging Reactive Oxygen Species for Remodeling Intestinal Homeostasis.

  2025cites this paper
• Immunohistochemistry Analysis in Inflammatory Bowel Disease—Should We Bring to Light Interleukin-10?

  2025cites this paper
• The Relationship Between CSF1R Signaling, Monocyte-Macrophage Differentiation, and Susceptibility to Inflammatory Bowel Disease

  2025cites this paper
• Autoimmunity in inflammatory bowel disease: a holobiont perspective.

  2025cites this paper
• Single-cell transcriptomic characterization of microscopic colitis

  2025cites this paper
• Year in Review: Selection of Best Papers in Gastroenterology and Hepatology 2024.

  2025cites this paper
• Mechanistic and therapeutic advances in immune-mediated gastrointestinal disorders.

  2025cites this paper
• Current paradigms in the management of inflammatory bowel disease

  2025cites this paper
• B cells in inflammatory bowel disease.

  2025cites this paper
• Case Report: Novel IL10RB variant causing very early onset-inflammatory bowel disease

  2025cites this paper
• Reshaping study design for faster extrapolation-based drug approval in pediatric inflammatory bowel diseases: An ESPGHAN-NASPGHAN position paper.

  2025cites this paper
• High mRNA Expression of 24 Dehydrocholesterol Reductase (DHCR24) in the Treatment of Doxorubicin-Induced Heart Failure in Rats

  2025cites this paper
• Advancing Inflammatory Bowel Disease Treatment by Targeting the Innate Immune System and Precision Drug Delivery

  2025cites this paper
• Inactivation of glutathione S-transferase alpha 4 blocks Enterococcus faecalis-induced bystander effect by promoting macrophage ferroptosis

  2025cites this paper
• The Monogenic Landscape of Human Infectious Diseases.

  2024cites this paper
• Key Interleukins in Inflammatory Bowel Disease—A Review of Recent Studies

  2024cites this paper
• Interleukin in Immune-Mediated Diseases: An Updated Review

  2024cites this paper
• Autoimmunity against cytokines: Double strike in autoimmune disease, a historical perspective

  2024cites this paper
• When a double negative is not a positive: Autoantibodies against IL-10 in patients with inflammatory bowel disease.

  2024cites this paper
• Ulcerative Colitis, LAIR1 and TOX2 Expression, and Colorectal Cancer Deep Learning Image Classification Using Convolutional Neural Networks

  2024cites this paper
• Common diagnostic biomarkers and molecular mechanisms of Helicobacter pylori infection and inflammatory bowel disease

  2024cites this paper
• Estimating the Number of Polygenic Diseases Among Six Mutually Exclusive Entities of Non-Tumors and Cancer

  2024cites this paper
• The mysteries of inflammatory bowel disease are being cracked — offering hope for new therapies

  2024cites this paper
• An integrative proteotranscriptomics approach reveals new ADAM9 substrates and downstream pathways

  2024cites this paper